MetaCap

Omeros Corporation (OMER)

NASDAQ: OMERHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.21-0.80 (-5.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OMER stock chart

Technical analysis

Key statistics

All statistics
Market cap
$983.66M
52-week range
6.70 – 21.24
Day range
13.07 – 13.88
Volume / Avg
2.02M / 1.36M
Beta
—

52-week range

$6.70$21.24

OMER stock today

Shares of Omeros (OMER) finished lower on Nov 20 at $13.21, a drop of 5.71% or $0.80 per share, versus the S&P 500's 3.70% decline. Shares are 37.8% below their 52-week high of $21.24, set on Sep 22, 2026 and 97.2% above the 52-week low of $6.70, in the middle of the past year's range. OMER is down 23.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 48.9%.

Omeros trades at 15.9x its trailing twelve-month earnings per share of $0.83. Its forward P/E of 12.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Omeros

Company profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Gregory A. Demopulos M.D.
Headquarters
Seattle, WA
Employees
175
IPO year
2009
Website
omeros.com

Financial highlights

Full financials

Omeros reported a net loss of $3.4 million, compared with a loss of $156.8 million a year earlier. Diluted earnings per share came in at -$0.05.

Omeros annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-3.35M$-156.81M$-117.81M$47.42M$194.24M
EPS (diluted)$-0.05$-2.70$-1.88$0.76$3.12

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$27.50+108.18%

  • Strong buy 0
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $22.00High $33.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.19 vs $-0.05
Surprise
-280.00%

OMER news

All OMER news

Omeros peers

Health Care sector
OMER peer companies
CompanyPrice% ChgMarket capCompare
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs OMER
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs OMER
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs OMER
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs OMER
SVRASavara Inc.4.26-18.23%$939.86Mvs OMER
CTYCity Therapeutics Inc.19.32+5.29%$1.03Bvs OMER
NKTRNektar Therapeutics30.20-7.19%$1.03Bvs OMER
JBIOJade Biosciences Inc.15.31+1.66%$1.06Bvs OMER

Indexes, lists and sector

Omeros stock FAQ

What is Omeros's stock price today?

OMER last traded at $13.21 as of Nov 20, 4:00 PM EST, down 5.71% on the day. Prices are delayed at least 15 minutes.

What is OMER's P/E ratio?

OMER trades at a trailing P/E ratio of 15.92 and a forward P/E of 11.95.

Who is Omeros's CEO?

Dr. Gregory A. Demopulos M.D. is the chief executive officer of Omeros Corporation, which has about 175 employees.

What is the OMER 52-week high?

The 52-week high for OMER is $21.24 and the 52-week low is $6.70. The stock is currently 37.8% below its high.

Compare OMER